Axim Biotechnologies Inc (OTCMKTS:AXIM) updated on the changes made to its advisory board. The firm has elected Dr. Donald Abrams as a new member to the board. Currently he is the Chief of the Hematology-Oncology segment at San Francisco General Hospital
George E. Anastassov, MD, who is the CEO of Axim, mentioned that they are honored and exhilarated to have Dr. Abrams become a part of their Advisory Board. In addition to being an oncology professional who was one of the initial clinicians to spot and define different AIDS-related issues, Dr. Abrams has expertise in medicinal cannabis research as well as clinical studies. Now with Axim, he will work to further enhance the intellectual rigor of firm’s research and help meet people needs with CBD related pharmaceutical solutions.
Commenting on his role with Axim, Dr. Abrams mentioned that he is exhilarated to be joining the advisory board as he is enthralled with firm’s unique technology aiming to formulate cannabis-based drugs accessible to patients via its fresh delivery mechanisms.
Dr. Abrams has been a part of clinical studies of unconventional and complementary drug intrusions for AIDS/ HIV and cancer, counting assessments of medical marijuana. He obtained financial support in 1997 from the “National Institute on Drug Abuse” to carry out clinical studies of the provisional safety of CBDs in HIV infection.
Axim posted that Dr. Abrams completed a pivotal trial of smoked cannabis in subjects with HIV-linked peripheral neuropathy and a study evaluating vaporization as a smokeless delivery tool for medicinal purposes.
Dr. Abram’s NIDA-supported study evaluated the probable pharmacokinetic contact between opioid analgesics and vaporized cannabis in subjects with chronic pain. He has been performing an NIH-funded trial evaluating vaporized cannabis in subjects with Sickle Cell disease.
In the last trading session, the stock price of Axim gained more than 4% to close the day at $12.10.
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies